

## Sun Pharma launches CEQUA for dry eyes treatment in the US

14 October 2019 | News

Sun Pharma introduces CEQUA SUPPORT<sup>™</sup> Specialty Pharmacy program to enable easy access for patients to obtain treatment



Sun Pharmaceutical Industries Ltd. has announced that one of its wholly-owned subsidiaries has commercialized CEQUA (cyclosporine ophthalmic solution) 0.09% in the U.S. CEQUA, which offers the highest concentration of cyclosporine for ophthalmic use approved by the U.S. Food and Drug Administration (FDA), is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye), an inflammatory disease that afflicts more than 16 million people in the U.S.

CEQUA is the first and only FDA-approved cyclosporine treatment delivered with nanomicellar (NCELL<sup>™</sup>) technology, which helps to improve the bioavailability and physicochemical stability of cyclosporine, resulting in improved ocular tissue penetration.

Sun Pharma is also introducing CEQUA SUPPORT<sup>™</sup> Specialty Pharmacy, a program designed to enable commercially insured patients to easily obtain CEQUA. Once a patient's prescription is submitted, CEQUA SUPPORT will provide several important services including insurance plan benefits verification, prior authorization support, and appeals assistance. This program is structured to minimize out-of-pocket cost and provides free home delivery.